A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)

Inclusion Criteria:

(Subjects who participated in ALK9072-003)

• Completed the ALK9072-003 Day 85 visit

• Continues to require treatment with an antipsychotic medication

(New Subjects)

• On a stable dose of oral antipsychotic medication

• Diagnosis of chronic schizophrenia based on Diagnostic and Statistical Manual ofMental Disorders, Fourth Edition (DSM-IV) criteria that is clinically stable

• Has been able to achieve outpatient status for more than 3 months prior to screening

• Body Mass Index (BMI) of 18.5 to 40.0 kg/m2 (inclusive)

• Resides in a stable living situation

Exclusion Criteria:

(Subjects who participated in ALK9072-003)

• Abnormal clinical laboratory, vital sign, or electrocardiogram (ECG) finding duringparticipation in study ALK9072-003 that was clinically relevant and related to studydrug

• Missed more than 1 scheduled study visit during participation in study ALK9072-003

• Has a significant or unstable medical condition that would preclude safe completion ofthe current study

• Subject is pregnant or breastfeeding

• Subject expects to be incarcerated in the next 12 months, or has pending legal actionwhich may impact compliance with study participation or procedures

(New Subjects)

• History of poor or inadequate clinical response to treatment with aripiprazole

• History of treatment resistance

• Diagnosis of current substance dependence (including alcohol)

• Pregnant, lactating, or breastfeeding

• Has received any long-acting intramuscular antipsychotic medication within 60 daysprior to screening

• Currently under involuntary hospitalization

• Current or expected incarceration Additional inclusion/exclusion criteria may apply